Cargando…

Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer

BACKGROUND: Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) predict the effects of fluoropyrimidine. However, the effects of FOLFOX therapy from the perspective of fluorouracil plus leucovorin (FL) remain underexplored. Hence, the relationship between mFOLFOX6 therapy (mFOLFOX6)...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Mitsuru, Katsumata, Kenji, Sumi, Tetsuo, Ishizaki, Tetsuo, Enomoto, Masanobu, Shigoka, Masatoshi, Wada, Takahiro, Kuwabara, Hiroshi, Mazaki, Junichi, Kasahara, Kenta, Tago, Tomoya, Udo, Ryutaro, Nagakawa, Yuichi, Kawachi, Shigeyuki, Tsuchida, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360946/
https://www.ncbi.nlm.nih.gov/pubmed/35345374
http://dx.doi.org/10.31557/APJCP.2022.23.3.1005
_version_ 1784764420843372544
author Watanabe, Mitsuru
Katsumata, Kenji
Sumi, Tetsuo
Ishizaki, Tetsuo
Enomoto, Masanobu
Shigoka, Masatoshi
Wada, Takahiro
Kuwabara, Hiroshi
Mazaki, Junichi
Kasahara, Kenta
Tago, Tomoya
Udo, Ryutaro
Nagakawa, Yuichi
Kawachi, Shigeyuki
Tsuchida, Akihiko
author_facet Watanabe, Mitsuru
Katsumata, Kenji
Sumi, Tetsuo
Ishizaki, Tetsuo
Enomoto, Masanobu
Shigoka, Masatoshi
Wada, Takahiro
Kuwabara, Hiroshi
Mazaki, Junichi
Kasahara, Kenta
Tago, Tomoya
Udo, Ryutaro
Nagakawa, Yuichi
Kawachi, Shigeyuki
Tsuchida, Akihiko
author_sort Watanabe, Mitsuru
collection PubMed
description BACKGROUND: Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) predict the effects of fluoropyrimidine. However, the effects of FOLFOX therapy from the perspective of fluorouracil plus leucovorin (FL) remain underexplored. Hence, the relationship between mFOLFOX6 therapy (mFOLFOX6) and therapeutic efficacy was evaluated in patients with advanced/recurrent colorectal cancer (CRC). METHODS: Correlations between TS and DPD and primary and metastatic lesions in recurrent CRC were analyzed. Univariate and multivariate analyses of TS and DPD in combination with response rate (RR), progression-free survival (PFS), and overall survival (OS) were performed. RESULTS: A positive correlation between DPD and primary and metastatic lesions; correlations between TS and RR, DPD and RR, and PFS and OS; and significant differences for RR and DPD and TS, PFS and DPD, and OS and DPD were obtained. CONCLUSION: Nucleic acid metabolizing enzymes in primary lesions can be used to predict mFOLFOX6 efficacy in patients with recurrent CRC.
format Online
Article
Text
id pubmed-9360946
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-93609462022-08-10 Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer Watanabe, Mitsuru Katsumata, Kenji Sumi, Tetsuo Ishizaki, Tetsuo Enomoto, Masanobu Shigoka, Masatoshi Wada, Takahiro Kuwabara, Hiroshi Mazaki, Junichi Kasahara, Kenta Tago, Tomoya Udo, Ryutaro Nagakawa, Yuichi Kawachi, Shigeyuki Tsuchida, Akihiko Asian Pac J Cancer Prev Research Article BACKGROUND: Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) predict the effects of fluoropyrimidine. However, the effects of FOLFOX therapy from the perspective of fluorouracil plus leucovorin (FL) remain underexplored. Hence, the relationship between mFOLFOX6 therapy (mFOLFOX6) and therapeutic efficacy was evaluated in patients with advanced/recurrent colorectal cancer (CRC). METHODS: Correlations between TS and DPD and primary and metastatic lesions in recurrent CRC were analyzed. Univariate and multivariate analyses of TS and DPD in combination with response rate (RR), progression-free survival (PFS), and overall survival (OS) were performed. RESULTS: A positive correlation between DPD and primary and metastatic lesions; correlations between TS and RR, DPD and RR, and PFS and OS; and significant differences for RR and DPD and TS, PFS and DPD, and OS and DPD were obtained. CONCLUSION: Nucleic acid metabolizing enzymes in primary lesions can be used to predict mFOLFOX6 efficacy in patients with recurrent CRC. West Asia Organization for Cancer Prevention 2022-03 /pmc/articles/PMC9360946/ /pubmed/35345374 http://dx.doi.org/10.31557/APJCP.2022.23.3.1005 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. https://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Research Article
Watanabe, Mitsuru
Katsumata, Kenji
Sumi, Tetsuo
Ishizaki, Tetsuo
Enomoto, Masanobu
Shigoka, Masatoshi
Wada, Takahiro
Kuwabara, Hiroshi
Mazaki, Junichi
Kasahara, Kenta
Tago, Tomoya
Udo, Ryutaro
Nagakawa, Yuichi
Kawachi, Shigeyuki
Tsuchida, Akihiko
Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer
title Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer
title_full Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer
title_fullStr Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer
title_full_unstemmed Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer
title_short Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer
title_sort nucleic acid metabolizing enzyme levels predict chemotherapy effects in advanced and recurrent colorectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360946/
https://www.ncbi.nlm.nih.gov/pubmed/35345374
http://dx.doi.org/10.31557/APJCP.2022.23.3.1005
work_keys_str_mv AT watanabemitsuru nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT katsumatakenji nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT sumitetsuo nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT ishizakitetsuo nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT enomotomasanobu nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT shigokamasatoshi nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT wadatakahiro nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT kuwabarahiroshi nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT mazakijunichi nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT kasaharakenta nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT tagotomoya nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT udoryutaro nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT nagakawayuichi nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT kawachishigeyuki nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer
AT tsuchidaakihiko nucleicacidmetabolizingenzymelevelspredictchemotherapyeffectsinadvancedandrecurrentcolorectalcancer